CD274 and cancer: This would have the advantage of maximizing T-cell reactivity by blocking the SHP2-mediated dephosphorylation of proximal TCR signal transducers, while triggering ADCC-like activity in CD16-CR transduced T-cells against PD-L1+ cancer cells, but no experiments have been done in this direction.